Literature DB >> 27347081

Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction.

Jiamin Niu1, Xia Han1, Huaxin Qi1, Jie Yin1, Zhiqiang Zhang1, Zengtang Zhang1.   

Abstract

The aim of the present study was to investigate the correlation between plasma the levels of vascular endothelial growth factor (VEGF) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). A total of 124 patients with AMI undergoing emergency percutaneous coronary intervention (PCI) were selected, and plasma VEGF levels were measured 7 days after the onset of AMI using an enzyme-linked immunosorbent assay. The patients were divided into the L (≤190 pg/ml VEGF) and H (>190 pg/ml VEGF) groups, and were followed up every 2 months for an average of 12 months. MACE were recorded during follow-up. On the basis of these results, the patients were further divided into the MACE and non-MACE (N-MACE) groups, and the serum VEGF concentration was compared between the two groups. At the 6-month follow-up, the incidence of MACE in the H group was found to be significantly reduced compared with the L group. The serum VEGF concentration in the N-MACE group was significantly higher compared with the MACE group. Multinomial logistic regression revealed that reduced VEGF levels (β=1.243; 95% CI, 1.018-1.326; P=0.026) were independent risk factors for MACE. In conclusion, high plasma VEGF levels at 7 days after AMI onset facilitate the long-term prognosis in the same infarct zone in patients with AMI, while low plasma VEGF levels are independent risk factors for MACE.

Entities:  

Keywords:  acute myocardial infarction; long-term prognosis; vascular endothelial growth factor

Year:  2016        PMID: 27347081      PMCID: PMC4906818          DOI: 10.3892/etm.2016.3286

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

Review 1.  Gene therapy for cardiovascular diseases.

Authors:  Marcin Gruchala; Himadri Roy; Shalini Bhardwaj; Seppo Ylä-Herttuala
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

Authors:  W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

3.  Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction.

Authors:  Takeshi Soeki; Yoshiyuki Tamura; Hisanori Shinohara; Koichi Sakabe; Yukiko Onose; Nobuo Fukuda
Journal:  Circ J       Date:  2002-11       Impact factor: 2.993

4.  Expression of vascular endothelial growth factor in patients with acute myocardial infarction.

Authors:  Y Hojo; U Ikeda; Y Zhu; M Okada; S Ueno; H Arakawa; H Fujikawa; T Katsuki; K Shimada
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

5.  Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction.

Authors:  H Ogawa; H Suefuji; H Soejima; K Nishiyama; K Misumi; K Takazoe; S Miyamoto; I Kajiwara; H Sumida; T Sakamoto; M Yoshimura; K Kugiyama; H Yasue; K Matsuo
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

Review 6.  Regulation of microvascular permeability by vascular endothelial growth factors.

Authors:  D O Bates; N J Hillman; B Williams; C R Neal; T M Pocock
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

7.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.

Authors:  Tobias Deuse; Christoph Peter; Paul W M Fedak; Tim Doyle; Hermann Reichenspurner; Wolfram H Zimmermann; Thomas Eschenhagen; William Stein; Joseph C Wu; Robert C Robbins; Sonja Schrepfer
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

9.  Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Eric Boersma; Andreas M Zeiher; Maarten L Simoons
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

10.  Hypoxia-inducible factor-1α and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats.

Authors:  Zhang Wang; Liang-Yi Si
Journal:  Ups J Med Sci       Date:  2013-02-26       Impact factor: 2.384

View more
  2 in total

1.  Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction.

Authors:  Kazuhiro Harada; Ryosuke Kikuchi; Hideki Ishii; Yohei Shibata; Susumu Suzuki; Akihito Tanaka; Atsuo Suzuki; Kenshi Hirayama; Toyoaki Murohara
Journal:  Int J Cardiol Heart Vasc       Date:  2018-03-22

2.  The Prominin-1-Derived Peptide Improves Cardiac Function Following Ischemia.

Authors:  Avner Adini; Irit Adini; Etty Grad; Yuval Tal; Haim D Danenberg; Peter M Kang; Benjamin D Matthews; Robert J D'Amato
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.